BACKGROUND: Heart failure with preserved ejection fraction (HFpEF) has become the most prevalent type of heart failure, but ...

The HFpEF Summit is a biannual, two-day meeting bringing together internationally recognized leaders in the clinical, biological, and translational study of HFpEF. This summit focused on the latest ...

The following is a summary of "Exploring the impact of metabolic comorbidities on epicardial adipose tissue in heart failure ...

A team of scientists led by Northwestern Medicine investigators have uncovered new details about a deadly heart condition ...

HealthDay News — In patients with heart failure with improved ejection fraction (EF), pharmacological therapy is rarely withdrawn, according to a study published online March 17 in Circulation.

Among iron-deficient patients with heart failure with reduced ejection fraction (HFrEF), receiving intravenous iron supplementation was found to be safe but resulted in mixed findings, according to a ...

Findings presented at the American College of Cardiology Annual Scientific Session indicate that finerenone's efficacy in ...

Managed Healthcare Executive gives C-suite executives in health plans and provider organizations news and strategies for ...

Tirzepatide offers a promising treatment for patients with obesity, chronic kidney disease, and heart failure, improving both ...

Heart failure with preserved ejection fraction (HFpEF) accounts for nearly half of all heart failure cases, but has limited disease-modifying therapeutics. SRD-002 is a gene therapy utilizing an ...